Jaffar Shabbar, Govender Thilo, Garrib Anupam, Welz Tanya, Grosskurth Heiner, Smith Peter G, Whittle Hilton, Bennish Michael L
Medical Research Council Tropical Epidemiology Group, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Trop Med Int Health. 2005 Apr;10(4):295-9. doi: 10.1111/j.1365-3156.2005.01390.x.
Many countries in Africa are planning to provide highly active antiretroviral therapy (HAART) to millions of people with acquired immune deficiency syndrome. This will be a highly complex therapy programme. Physician-based models of care adapted from industrialized countries will not succeed in providing treatment to the majority of those who need it in resource-constrained settings. A high priority is to identify care models for Africa that will increase coverage of HAART safely and effectively: key issues are (i) whether nursing staff or non-clinically qualified staff can take the major role in the treatment programme and reduce the workload of physicians, (ii) whether treatment and monitoring can be delivered through peripheral health centres or through home visits and achieve better adherence and be more cost-effective than delivery at hospitals and (iii) which clinical algorithms used by nursing or non-clinically qualified staff will be effective for screening, diagnosing and managing treatment-related side-effects and medical problems being incurred. Many current ART support programmes are making little or no investment in research, but answering important questions on delivery of HAART will be essential if HAART programmes are to be successful in African nations with a high burden of human immunodeficiency virus infection.
非洲许多国家正计划为数以百万计的获得性免疫缺陷综合征患者提供高效抗逆转录病毒疗法(HAART)。这将是一个高度复杂的治疗项目。照搬工业化国家以医生为主的护理模式,无法成功地为资源有限地区的大多数有需求者提供治疗。当务之急是确定适合非洲的护理模式,以安全有效地扩大HAART的覆盖范围:关键问题包括:(i)护理人员或无临床资质的工作人员能否在治疗项目中发挥主要作用并减轻医生的工作量;(ii)治疗和监测能否通过基层医疗中心或家访进行,并且在依从性方面优于医院治疗,同时更具成本效益;(iii)护理人员或无临床资质的工作人员使用哪种临床算法来有效筛查、诊断和处理治疗相关的副作用及出现的医疗问题。目前许多抗逆转录病毒治疗支持项目在研究方面投入甚少或根本没有投入,但如果HAART项目要在人类免疫缺陷病毒感染负担沉重的非洲国家取得成功,回答有关HAART实施的重要问题至关重要。